Wilson’s Disease (Copper Toxicosis) – A Comprehensive Guide

Overview

Wilson’s disease (also called hepatolenticular degeneration) is a rare, autosomal‑recessive genetic disorder that impairs the body’s ability to eliminate excess copper. The copper accumulates primarily in the liver, brain, cornea, and kidneys, leading to progressive organ damage.

• Who it affects: Both sexes equally; symptoms usually appear between ages 5–35, but diagnosis can occur at any age.
• Prevalence: Estimated 1 in 30,000–50,000 individuals worldwide, with carrier frequency of roughly 1 in 90‑100 people.¹
• Genetics: Caused by mutations in the ATP7B gene on chromosome 13, which encodes a copper‑transporting ATPase needed for bile excretion of copper.

Symptoms

Symptoms result from copper buildup in different organs. The clinical picture is highly variable; patients may present with hepatic, neurologic, psychiatric, or ocular signs, sometimes simultaneously.

Hepatic (Liver) Manifestations

• Asymptomatic elevation of liver enzymes: Often the first clue, especially in children.
• Hepatitis – fatigue, right‑upper‑quadrant discomfort, jaundice.
• Cirrhosis – portal hypertension, ascites, variceal bleeding.
• Acute liver failure – rare but life‑threatening; may require transplantation.

Neurologic Manifestations

• Movement disorders – tremor, dystonia, chorea, parkinsonism‑like rigidity.
• Speech changes – dysarthria, slurred speech.
• Coordination problems – gait ataxia, limb clumsiness.
• Peripheral neuropathy – numbness, tingling.

Psychiatric Manifestations

• Personality changes, irritability, depression, anxiety.
• Psychosis, hallucinations, or cognitive decline in advanced disease.

Ocular Manifestations

• Körner’s ring – brownish‑gold deposition at the Descemet membrane of the cornea, visible on slit‑lamp exam.
• Kayser–Fleischer (KF) rings – similar copper deposits seen in the peripheral cornea; present in >90 % of neurologic cases and ~50 % of hepatic‑only cases.

Renal and Other Manifestations

• Proteinuria, hematuria, or renal tubular dysfunction.
• Hemolytic anemia (especially during acute liver decompensation).
• Musculoskeletal pain, arthropathy.

Causes and Risk Factors

Wilson’s disease is inherited; a child must receive a defective ATP7B gene from each parent to develop disease.

• Genetic mutations: Over 500 pathogenic variants identified; the most common worldwide is c.3207C>A (p.His1069Gln).
• Carrier status: Heterozygous carriers are asymptomatic but can pass the mutant gene to offspring.
• Consanguinity: Increases risk because relatives are more likely to share the same mutant allele.
• Ethnicity: Higher carrier frequency reported in certain populations (e.g., people of Mediterranean descent).

Diagnosis

Because symptoms overlap with many other conditions, a combination of clinical, laboratory, and imaging studies is required. The Leipzig scoring system (2001) remains the standard diagnostic algorithm; a score ≥4 indicates Wilson’s disease.

Laboratory Tests

• Serum ceruloplasmin: Typically <30 mg/dL (low). However, 10‑20 % of patients may have normal levels.
• 24‑hour urinary copper excretion: >100 µg/24 h (or >40 µg/24 h after a copper challenge) supports diagnosis.
• Serum copper: Often low because most copper is sequestered in tissues.
• Liver function tests: ALT, AST, bilirubin, alkaline phosphatase – may be elevated.
• Complete blood count: May reveal hemolytic anemia.

Ophthalmic Examination

• Slit‑lamp detection of Kayser–Fleischer rings (present in >95 % of neurologic cases).

Imaging & Histology

• Magnetic resonance imaging (MRI) of brain: Hyperintensities in basal ganglia, thalamus, brainstem – characteristic but not pathognomonic.
• Liver biopsy: Quantitative copper >250 µg/g dry weight confirms hepatic accumulation; also allows assessment of fibrosis.

Genetic Testing

Sequencing of the ATP7B gene confirms the diagnosis, identifies carriers, and aids family counseling. Recommended when clinical tests are inconclusive.

Treatment Options

Goal: reduce copper accumulation, prevent organ damage, and maintain normal copper balance for life.

First‑Line Chelation Therapy

• Penicillamine (Cuprimine®) – 250‑1500 mg/day divided doses. Binds copper for urinary excretion. Requires monitoring for side effects (rash, nephrotoxicity, bone marrow suppression).
• Trientine (Syprine®) – 750‑1500 mg/day. Often used when penicillamine is intolerable.

Zinc Therapy

Zinc acetate (50 mg elemental zinc 3× daily) blocks intestinal copper absorption via induction of metallothionein. Useful as maintenance after initial chelation or in presymptomatic patients.

Alternative/Adjunctive Agents

• Dimercaprol (British anti‑Lewisite) – reserved for acute copper poisoning; not first‑line for chronic Wilson’s.
• Tetrathiomolybdate (TTM) – investigational; shows promise in clinical trials but not yet FDA‑approved.

Liver Transplantation

Indicated for acute liver failure, end‑stage cirrhosis, or refractory neurologic disease. Post‑transplant, the new liver restores copper excretion, often curing the metabolic defect.

Lifestyle & Dietary Modifications

• Limit high‑copper foods: shellfish, liver, kidneys, nuts, chocolate, mushrooms, dried fruits, and copper‑catalyzed cookware.
• Avoid vitamin C megadoses (>1 g/day) which can increase copper absorption.
• Maintain adequate hydration to facilitate urinary copper excretion.

Living with Wilson’s Disease (Copper Toxicosis)

Medication Adherence

Take chelators or zinc exactly as prescribed. Missed doses can quickly lead to copper re‑accumulation.

Regular Monitoring

• Every 3–6 months: serum ceruloplasmin, 24‑hour urinary copper, liver enzymes, complete blood count.
• Annual MRI (or sooner if neurologic symptoms change) to track brain involvement.
• Ophthalmologic exam annually for KF rings.

Nutrition & Cooking Tips

• Use stainless steel or glass cookware; avoid copper pots unless lined.
• Read food labels; many commercially prepared foods list copper content.
• Incorporate a balanced diet rich in fruits, vegetables, lean protein, and whole grains while respecting copper restrictions.

Psychosocial Support

Because depression and anxiety are common, consider counseling, support groups, or psychiatric medication when needed. Educate family members about the disease to foster a supportive environment.

Family Screening

First‑degree relatives should undergo serum ceruloplasmin and genetic testing even if asymptomatic. Early detection enables pre‑emptive treatment, preventing irreversible damage.

Prevention

While the genetic defect cannot be prevented, certain strategies reduce the risk of disease manifestation or complications:

• Genetic counseling: Couples with a known carrier status can discuss reproductive options (e.g., IVF with pre‑implantation genetic diagnosis).
• Newborn screening: Not routine worldwide, but some regions incorporate copper metabolism markers in pilot programs.
• Early treatment of identified carriers: Initiating zinc therapy in asymptomatic children can delay disease onset.

Complications

If untreated or inadequately managed, copper toxicity leads to severe, sometimes irreversible complications:

• Advanced cirrhosis → portal hypertension, hepatic encephalopathy, hepatocellular carcinoma.
• Neurologic degeneration → permanent movement disorders, severe cognitive impairment.
• Acute hemolytic anemia → renal failure, cardiovascular collapse.
• Psychiatric crises (suicidality) due to neurochemical disturbances.
• Liver transplant rejection or recurrence of copper overload if chelation is stopped post‑transplant.

When to Seek Emergency Care

References

1. Mayo Clinic. Wilson Disease – Symptoms and Causes. https://www.mayoclinic.org
2. National Institute of Diabetes and Digestive and Kidney Diseases. Wilson Disease. https://www.niddk.nih.gov
3. Cleveland Clinic. Wilson Disease – Diagnosis and Treatment. https://my.clevelandclinic.org
4. American Association for the Study of Liver Diseases. Practice Guidelines for Wilson Disease, 2022. https://aasld.org
5. World Health Organization. Rare Diseases: An Overview. 2020. https://www.who.int